FDA approves immunotherapy for chronic lymphocytic leukemia (CLL)

The U.S. Food and Drug Administration has approved GlaxoSmithKline's monoclonal antibody ofatumumab (to be marketed as Arzerra) for the treatment of chronic lymphocytic leukemia (CLL) in patients whose cancer is considered relapsed or refractory.

The FDA approved ofatumumab under its accelerated approval process.

“The approval of Arzerra illustrates FDA's commitment to using the accelerated approval process to approve drugs for patients who have limited therapeutic options,” said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research.

Side effects or adverse events associated with ofatumumab include increased risk of developing progressive multifocal leukoencephalopathy (PML), a brain infection that is generally fatal. This makes Arzerra at least the second monoclonal antibody with potential links to PML, the other being the widely used Rituxan (rituximab).

Those patients considered at high risk for Hepatitis B should be screened before being treated with ofatumumab. Patients with evidence of inactive hepatitis should be monitored for re-activation of the infection during and after completing treatment.

The question is whether this extends to small lymphocytic lymphoma (SLL), as even the World Health Organization considers CLL and SLL to be the same disease.

Ofatumumab is in trials to test its efficacy in treating both follicular lymphoma and diffuse large b-cell lymphoma.

Source: FDA press release

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap